PHCCC: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== PHCCC == | |||
[[File:PHCCC_structure.png|thumb|right|Chemical structure of PHCCC]] | |||
'''PHCCC''' is a chemical compound that acts as a positive allosteric modulator of the [[metabotropic glutamate receptor]] subtype 4 (mGluR4). It is of interest in the field of [[neuroscience]] and [[pharmacology]] for its potential therapeutic effects in various neurological disorders. | |||
PHCCC | |||
== | === Chemical Properties === | ||
PHCCC is a synthetic compound. Its chemical | PHCCC is a synthetic compound with a specific chemical structure that allows it to interact with mGluR4. The structure of PHCCC is shown in the image to the right. Its chemical formula is C<sub>18</sub>H<sub>14</sub>ClNO<sub>2</sub>, and it has a molecular weight of 311.76 g/mol. | ||
== | === Mechanism of Action === | ||
PHCCC functions as a positive allosteric modulator, meaning it binds to a site on the mGluR4 receptor that is distinct from the active site. This binding enhances the receptor's response to its natural ligand, [[glutamate]]. By modulating mGluR4 activity, PHCCC can influence [[synaptic transmission]] and [[neurotransmitter]] release in the [[central nervous system]]. | |||
== | === Potential Therapeutic Applications === | ||
Research into PHCCC has suggested potential applications in treating [[neurological disorders]] such as [[Parkinson's disease]], [[anxiety]], and [[schizophrenia]]. By modulating mGluR4, PHCCC may help to restore balance in neurotransmitter systems that are disrupted in these conditions. | |||
=== Research and Development === | |||
Studies on PHCCC have primarily been conducted in [[preclinical]] settings, using [[animal models]] to assess its efficacy and safety. These studies have shown promising results, but further research is needed to determine its potential as a therapeutic agent in humans. | |||
== Related Pages == | |||
* [[Metabotropic glutamate receptor]] | * [[Metabotropic glutamate receptor]] | ||
* [[Allosteric modulator]] | * [[Allosteric modulator]] | ||
* [[ | * [[Neurotransmitter]] | ||
* [[Parkinson's disease]] | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Neuroscience]] | [[Category:Neuroscience]] | ||
Latest revision as of 03:36, 13 February 2025
PHCCC[edit]
PHCCC is a chemical compound that acts as a positive allosteric modulator of the metabotropic glutamate receptor subtype 4 (mGluR4). It is of interest in the field of neuroscience and pharmacology for its potential therapeutic effects in various neurological disorders.
Chemical Properties[edit]
PHCCC is a synthetic compound with a specific chemical structure that allows it to interact with mGluR4. The structure of PHCCC is shown in the image to the right. Its chemical formula is C18H14ClNO2, and it has a molecular weight of 311.76 g/mol.
Mechanism of Action[edit]
PHCCC functions as a positive allosteric modulator, meaning it binds to a site on the mGluR4 receptor that is distinct from the active site. This binding enhances the receptor's response to its natural ligand, glutamate. By modulating mGluR4 activity, PHCCC can influence synaptic transmission and neurotransmitter release in the central nervous system.
Potential Therapeutic Applications[edit]
Research into PHCCC has suggested potential applications in treating neurological disorders such as Parkinson's disease, anxiety, and schizophrenia. By modulating mGluR4, PHCCC may help to restore balance in neurotransmitter systems that are disrupted in these conditions.
Research and Development[edit]
Studies on PHCCC have primarily been conducted in preclinical settings, using animal models to assess its efficacy and safety. These studies have shown promising results, but further research is needed to determine its potential as a therapeutic agent in humans.
